-transparent.png){kind=logo}
A series of HIV-1 protease inhibitors based on the lead compound Pc (IC50 = 165 nmol/l) with structural modifications at P1/P1' substituents or with a lengthening at its core unit were synthesized from amino acid starting materials. All analogues were less active than Pc against the protease.
Related Publications
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
January 1999,
Pharmacotherapy,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
December 2003,
The Pediatric infectious disease journal,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
June 1996,
Bioorganicheskaia khimiia,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
July 2005,
Antimicrobial agents and chemotherapy,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
May 1992,
Biochemistry and cell biology = Biochimie et biologie cellulaire,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
March 1998,
Medicina clinica,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
August 2008,
Chemical & pharmaceutical bulletin,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
May 1997,
Archives of internal medicine,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
June 2002,
The Journal of infectious diseases,
M Marastoni, and
M Bazzaro, and
F Bortolotti, and
R Tomatis
October 2002,
Antimicrobial agents and chemotherapy,
